Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitiglinide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 7/20 | 0.53 |
| ▸ | CPA3 | P15088 | 3/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitiglinide SCHEMBL876930 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL2864873 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL49085 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4457950 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9049521 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4457953 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL6135224 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL305840 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047711 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047718 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178794-B1 | USE OF SUCCINIC ACID DERIVATIVES TO OBTAIN A MEDICINE FOR TREATING INFLAMMATION | SANOFI AVENTIS (FR) | 2005-09-07 | — | — | EP | claimed |
| EP-0507534-B1 | Succinic acid compounds | KISSEI PHARMACEUTICAL (JP) | 1996-02-28 | — | — | EP | claimed |
| US-20240194304-A1 | Prediction Method, Prediction Device, and Prediction Program for New Indication of Desired Known Drug or Equivalent Material Thereof | KARYDO THERAPEUTIX, INC. (JP) | 2024-06-13 | — | — | US | disclosed |
| CN-114890933-B | Preparation method of racemic mitiglinide | 恒升德康(南京)医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-114890933-A | Preparation method of racemic mitiglinide | 恒升德康(南京)医药科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-110568100-B | Mitiglinide calcium R-isomer detection method | 江西金水宝制药有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-11020378-B2 | Compounds, compositions and methods for treating insulin resistance | UNIV PARIS DESCARTES (FR) | 2021-06-01 | — | — | US | disclosed |
| CN-112557566-A | Method for detecting corresponding isomer of mitiglinide calcium intermediate S-benzylsuccinic acid | 江西济民可信药业有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3482753-B1 | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2021-01-27 | — | — | EP | disclosed |
| EP-3065723-B1 | COMPOUNDS FOR THE TREATMENT OF DIABETES AND DISEASE COMPLICATIONS ARISING FROM SAME | BEN GURION UNIV OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2020-09-23 | — | — | EP | disclosed |
| US-20200222409-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2020-07-16 | — | — | US | disclosed |
| EP-1357928-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | New River Pharmaceuticals Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | BUSSOLARI JACQUELINE C (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003079972-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PARMACEUTICALS INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003007951-A1 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF DIABETES | N-GENE RESEARCH LABORATORIES INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-0967204-A1 | PROCESS FOR PRODUCING BENZYLSUCCINIC ACID DERIVATIVES | Kissei Pharmaceutical Co. Ltd. (JP) | 1999-12-29 | — | — | EP | disclosed |
| EP-0507534-B1 | Succinic acid compounds | KISSEI PHARMACEUTICAL (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-5202335-A | Hypoglycemic, antidiabetic agents | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0507534-A1 | Succinic acid compounds | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020378-B2 | Compounds, compositions and methods for treating insulin resistance | GPR119, INSR, GRK4 | CPA1 4111/4885CPA3 3935/4885CPB1 2357/4885 |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | GPR119, SLC2A4, SLC2A1 | CPA1 2707/4885CPA3 4348/4885CPB1 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.